Patents Assigned to Critical Care Diagnostics, Inc.
-
Patent number: 9523696Abstract: Methods using biomarkers, e.g., serum levels of ST2, to predict risk of developing hypertension, as well as methods for treating subjects to reduce the risk of developing hypertension and methods for selecting and/or stratifying subjects for clinical trials of treatments to reduce the risk of hypertension.Type: GrantFiled: August 16, 2013Date of Patent: December 20, 2016Assignee: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Patent number: 9239333Abstract: Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the kit to evaluate the risk of an adverse clinical outcome in a subject, to decide whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis) or to initiate or terminate treatment, to select a subject for participation in a clinical study, and/or to select treatment for a subject.Type: GrantFiled: May 1, 2014Date of Patent: January 19, 2016Assignee: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Patent number: 9150654Abstract: Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.Type: GrantFiled: March 1, 2013Date of Patent: October 6, 2015Assignee: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Patent number: 9057733Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.Type: GrantFiled: March 7, 2013Date of Patent: June 16, 2015Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson
-
Publication number: 20150081224Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: ApplicationFiled: April 3, 2014Publication date: March 19, 2015Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Eugene R. Heyman
-
Publication number: 20140286944Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: ApplicationFiled: June 9, 2014Publication date: September 25, 2014Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Publication number: 20140234875Abstract: Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the kit to evaluate the risk of an adverse clinical outcome in a subject, to decide whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis) or to initiate or terminate treatment, to select a subject for participation in a clinical study, and/or to select treatment for a subject.Type: ApplicationFiled: May 1, 2014Publication date: August 21, 2014Applicant: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Patent number: 8748110Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: GrantFiled: July 18, 2012Date of Patent: June 10, 2014Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Patent number: 8728742Abstract: Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation 5 in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 and a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the in the methods described.Type: GrantFiled: March 16, 2012Date of Patent: May 20, 2014Assignee: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Publication number: 20140058743Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: ApplicationFiled: August 21, 2013Publication date: February 27, 2014Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Publication number: 20140051773Abstract: Methods using biomarkers, e.g., serum levels of ST2, to predict risk of developing hypertension, as well as methods for treating subjects to reduce the risk of developing hypertension and methods for selecting and/or stratifying subjects for clinical trials of treatments to reduce the risk of hypertension.Type: ApplicationFiled: August 16, 2013Publication date: February 20, 2014Applicant: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Patent number: 8617825Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.Type: GrantFiled: July 8, 2011Date of Patent: December 31, 2013Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson
-
Publication number: 20130345805Abstract: Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting, replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT, or CRT-D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in, or stratifying a subject participating in, a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in a subject. Also provided are kits for performing any of these methods.Type: ApplicationFiled: May 17, 2013Publication date: December 26, 2013Applicants: CARDIAC PACEMAKERS, INC., CRITICAL CARE DIAGNOSTICS, INC.Inventors: James V. SNIDER, Timothy Edward MEYER, Craig Michael STOLEN, Robert W. GERWIEN
-
Publication number: 20130244236Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: ApplicationFiled: March 6, 2013Publication date: September 19, 2013Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Eugene R. Heyman
-
Publication number: 20130177931Abstract: Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.Type: ApplicationFiled: March 1, 2013Publication date: July 11, 2013Applicant: CRITICAL CARE DIAGNOSTICS, INC.Inventor: Critical Care Diagnostics, Inc.
-
Patent number: 8420785Abstract: Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.Type: GrantFiled: April 8, 2011Date of Patent: April 16, 2013Assignee: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Publication number: 20130071404Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: ApplicationFiled: July 18, 2012Publication date: March 21, 2013Applicant: CRITICAL CARE DIAGNOSTICS, INC.Inventors: James V. Snider, Robert W. Gerwien
-
Publication number: 20120276551Abstract: Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation 5 in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 and a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the in the methods described.Type: ApplicationFiled: March 16, 2012Publication date: November 1, 2012Applicant: CRITICAL CARE DIAGNOSTICS, INC.Inventor: James V. Snider
-
Patent number: 8090562Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: GrantFiled: April 17, 2009Date of Patent: January 3, 2012Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Eugene R. Heyman
-
Patent number: D770057Type: GrantFiled: September 23, 2014Date of Patent: October 25, 2016Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, David Geliebter